文献速递骨软组织肉瘤与黑色素瘤

CPI耐药黑色素瘤中分离的T细胞具备功能并可介导肿瘤消退

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
PubMed 文献 · Ann Oncol · 2018-01-01

本研究探讨CPI治疗后进展的转移性黑色素瘤患者能否产生功能性肿瘤特异性免疫反应。从23个进展病灶分离扩增TIL,83%可识别自体肿瘤,CD8+和CD4+ TIL均具识别能力;12例CPI耐药患者接受TIL联合化疗及细胞因子治疗,2例部分缓解。

要点

  • CPI耐药黑色素瘤病灶中仍存在功能性肿瘤反应性T细胞。
  • 83%患者TIL可识别自体肿瘤,CD8+中位23%识别肿瘤细胞。
  • 12例CPI耐药患者TIL治疗后2例部分缓解。

核心结论

  • CPI治疗失败患者的肿瘤微环境中仍大量浸润肿瘤反应性T细胞。
  • 这些患者仍可对未筛选的自体TIL输注产生应答。
  • 结果支持在多重CPI治疗失败的黑色素瘤患者中进一步测试新型免疫再激活策略。

研究设计与样本

  • 从CPI治疗后进展的转移性黑色素瘤病灶分离扩增TIL,用共培养试验评估肿瘤特异性免疫反应。
  • 23个转移灶来自个体患者,所有病灶在抗PD-1治疗中或之后进展(23/23,100%),多数也在抗CTLA-4后进展(17/23,74%)。
  • I/II期临床试验中,12例CPI耐药黑色素瘤患者接受TIL联合淋巴细胞清除化疗、pegIFNα2b和白细胞介素-2治疗。

主要发现

  • 19/23患者(83%)检测到功能性抗肿瘤免疫反应。
  • CD8+ TIL在18/23患者(78%)中能识别自体肿瘤,CD4+ TIL在16/23患者(70%)中能识别自体肿瘤。
  • CD8+ TIL中识别肿瘤细胞的比例中位数为23%(范围1.0%-84%),与既往未选择转移性黑色素瘤患者队列相似。
  • 瘤内免疫浸润定位在样本间存在异质性。
  • 12例既往CPI治疗失败患者中,TIL治疗导致2例部分缓解,其中1例持续中。

临床怎么用

  • CPI耐药后不应仅凭影像进展判定免疫系统完全失能,TIL中仍可检出肿瘤反应性T细胞。
  • 对多重CPI治疗失败的黑色素瘤患者,未筛选自体TIL输注联合淋巴细胞清除化疗及细胞因子是值得研究的选择。

局限性

  • TIL临床结果来自小样本I/II期试验(12例),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Almost half of the patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study, we investigated whether the immune system of patients progressing following CPI treatment was able to generate functional tumor-specific immune responses. MATERIALS AND METHODS: Tumor-infiltrating lymphocytes (TILs) were isolated and expanded from metastatic melanoma lesions which progressed during or after anti-programmed cell death protein 1 (PD)-1 and anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) treatment. Tumor-specific immune responses were assessed with co-culture assays of TILs and autologous tumor cells. RESULTS: TILs from 23 metastases of individual patients could be assessed for T cells recognition of autologous tumor cells. All metastases were progressive on or following anti-PD-1 (23/23, 100%), and the majority also after anti-CTLA-4 (17/23, 74%). Functional antitumor immune responses were detected in 19/23 patients (83%). Both CD8+ (in 18/23 patients, 78%) and CD4+ (in 16/23 patients, 70%) TILs were able to recognize autologous tumors. A large fraction of CD8+ TILs (median 23%, range 1.0%-84%) recognized tumor cells. This is similar to the cohorts of unselected patient populations with metastatic melanoma presented in previous studies. The localization of intratumoral immune infiltrates was heterogeneous among samples. In a phase I/II clinical trial, TILs were administered with lymphodepleting chemotherapy, pegIFNα2b and interleukin-2 to 12 patients with CPI-resistant melanoma. Out of 12 patients who previously failed CPI therapy, treatment with TILs resulted in two partial responses, of which one is ongoing. CONCLUSIONS: Tumor-reactive T cells appear to heavily infiltrate the tumor microenvironment of patients who failed previous CPI treatment. These patients can still respond to an infusion of unselected autologous TILs. Our results warrant further testing of novel immune re-activation strategies in melanoma patients who failed multiple CPI therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Andersen R, Borch TH, Draghi A, et al. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Ann Oncol. 2018. PMID: 29688262. doi:10.1093/annonc/mdy139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。